Funders › RI › Dr Ralph & Marian Falk Medical Research TR › 2024
Grants paid by Dr Ralph & Marian Falk Medical Research TR, tax year 2024
EIN 36-6975534 · Dallas, RI · Form 990-PF, Part XV
In tax year 2024, Dr Ralph & Marian Falk Medical Research TR (EIN 36-6975534) reported 37 grants paid totaling $7,805,072. Dataset version 2026.09.0, built 2026-09-03.
Every grant, 2024
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2024 | University of Cincinnati Cleveland, OH | U | $497,018 | paid | INHIBITORS TARGETING PEANUT | 202540939349101804 |
| 2024 | Brown University of Providence Providence, RI | B | $495,146 | paid | ANTI-MALARIA DRUGS TARGETNG | 202540939349101804 |
| 2024 | Medical College of Wisconsin Milwaukee, WI | B | $377,004 | paid | NEW DRUGS TO TREAT | 202540939349101804 |
| 2024 | Case Western Reserve University Cleveland, OH | U | $343,159 | paid | B CELL CANCER THERAPY USING | 202540939349101804 |
| 2024 | Cleveland Clinic Foundation Cleveland, OH | C | $336,255 | paid | DEVELOPMENT OF NEW DRUG FOR | 202540939349101804 |
| 2024 | Thomas Jefferson University Philadelphia, PA | B | $333,333 | paid | PROTACS FOR TARGETING BRCA | 202540939349101804 |
| 2024 | Medical College of Wisconsin Milwaukee, WI | B | $318,948 | paid | DEVELOPMENT OF SENSORY | 202540939349101804 |
| 2024 | Universityof Minnesota Minneapolis, MN | U | $235,086 | paid | THYROID HORMONE | 202540939349101804 |
| 2024 | University of Chicago Chicago, IL | U | $200,685 | paid | TUMOR ANUEPLOIDY - | 202540939349101804 |
| 2024 | Ohio State University Columbus, OH | U | $197,879 | paid | DEVELOP NEW THERAPY FOR | 202540939349101804 |
| 2024 | Regents of University of Michigan Ann Arbor, MI | D | $190,000 | paid | DEVICE TO PREDICT | 202540939349101804 |
| 2024 | Childrens Hospital Medical Center Cincinnati, OH | B | $190,000 | paid | LUPUS NEPHRITIS BIOMARKERS | 202540939349101804 |
| 2024 | Cleveland Clinic Foundation Cleveland, OH | C | $190,000 | paid | NEW WEAPONS TO FIGHT | 202540939349101804 |
| 2024 | Yale University School of Medicine New Haven, CT | U | $190,000 | paid | TARGETED DEGREDATION OF | 202540939349101804 |
| 2024 | State University of Iowa Iowa City, IA | D | $187,210 | paid | IMPROVE HYPOXIC TUMOR MGMT | 202540939349101804 |
| 2024 | Mayo Clinic Rochester, MN | U | $181,905 | paid | IN VIVO GENERATION OF CAR T | 202540939349101804 |
| 2024 | Indiana University Bloomington, IN | C | $179,775 | paid | TRAUMATIC BRAIN INJURY | 202540939349101804 |
| 2024 | Rehabilitation Institute of Chicago Chicago, IL | B | $177,796 | paid | REPURPOSE 5-AZACYTIDINE - | 202540939349101804 |
| 2024 | Indiana University Bloomington, IN | C | $177,271 | paid | NOVEL MINIMALLY INVASIVE | 202540939349101804 |
| 2024 | Stanford University Stanford, CA | C | $176,215 | paid | METABOLIC PAUSING - ORGAN | 202540939349101804 |
| 2024 | Washington University St Louis, MO | C | $175,216 | paid | ZIKA VIRUS GENETIC ARMING- | 202540939349101804 |
| 2024 | Board Regents of University of Wisconsin Milwaukee, WI | U | $175,000 | paid | DIABETES STEM CELL CURE - | 202540939349101804 |
| 2024 | Brown University of Providence Providence, RI | B | $175,000 | paid | REPURPOSING CLOPIDOGREL TO | 202540939349101804 |
| 2024 | Case Western Reserve University Cleveland, OH | U | $175,000 | paid | BLOCKING PEPTIDE TREATMENT | 202540939349101804 |
| 2024 | University of Cincinnati Cleveland, OH | U | $175,000 | paid | DEVELOP IMPROVED METHOD OF | 202540939349101804 |
| 2024 | University of Chicago Chicago, IL | U | $175,000 | paid | DEVELOPMENT OF SYNGAP1 | 202540939349101804 |
| 2024 | Michigan State University East Lansing, MI | U | $175,000 | paid | DEVELOP NEW ODC INHIBITORS | 202540939349101804 |
| 2024 | Mayo Clinic Rochester, MN | U | $174,425 | paid | CD-19 TARGETED CAR-MSC19 IN | 202540939349101804 |
| 2024 | University of Minnesota Minneapolis, MN | U | $173,673 | paid | DEVELOP IL-15 - MALARIA | 202540939349101804 |
| 2024 | Yale University School of Medicine New Haven, CT | U | $173,017 | paid | DEVELOP PHAGE THERAPY TO | 202540939349101804 |
| 2024 | University of Minnesota Minneapolis, MN | U | $168,835 | paid | SEVERITY MEASURE- ADDUCTOR | 202540939349101804 |
| 2024 | Stanford University Stanford, CA | C | $163,974 | paid | NOVEL DNA-GUIDED ARGONAUTE | 202540939349101804 |
| 2024 | Thomas Jefferson University Philadelphia, PA | B | $150,887 | paid | CHEMOKINE ANTAGONIST FOR | 202540939349101804 |
| 2024 | University of Cincinnati Cleveland, OH | U | $145,339 | paid | TARGETING SEXUAL CYCLE OF | 202540939349101804 |
| 2024 | University of Cincinnati Cleveland, OH | U | $136,995 | paid | LETROZOLE- NOVEL | 202540939349101804 |
| 2024 | Indiana University Bloomington, IN | C | $100,000 | paid | NOVEL RXR AGONIST FOR | 202540939349101804 |
| 2024 | Northwestern University Evanston, IL | B | $18,026 | paid | T CELL THERAPY FOR | 202540939349101804 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Derived from IRS Form 990-PF e-file XML. Dataset version 2026.09.0, built 2026-09-03. All years for this funder.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.